IMR Press / EJGO / Volume 39 / Issue 6 / DOI: 10.12892/ejgo4677.2018

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Could there be a role for the antidiabetic drug metformin in oncological treatment?
Show Less
1 Department of Perinatology and Women's Diseases, Poznan University of Medical Sciences, Poznan, Poland
2 Department of Gynecological Surgery, Poznan University of Medical Sciences, Poznan, Poland
3 Department of Oncology, Poznan University of Medical Sciences, Poland
4 Department of Bioorganic Chemistry, Faculty of Chemistry, Adam Mickiewicz University, Poznan, Poland
Eur. J. Gynaecol. Oncol. 2018, 39(6), 867–870;
Published: 10 December 2018

Diabetes and tumour diseases are serious health problems in the elderly population. Several studies have suggested that patients with diabetes are at significantly higher risk of cancer. On the other hand, epidemiologic evidence suggests that some drugs used to treat hyperglycemia are associated with reduced risk of cancer. Metformin, the drug applied in type 2 diabetes, has been shown to reduce incidence and mortality due to malignant tumours in various localities. A hypothesis is presented which seeks to explain the anticancer effects of metformin. Empirical data from the scientific literature is used to support the hypothesis that metformin restricts the growth of human cancer stem cells (CSCs). The LKB1/AMPK (liver kinase B1/AMP activated protein kinase) mechanism of the antineoplastic action is pleiotropic, involving the activation of the LKB1/AMP pathway, which inhibits mTOR signalling, inhibits STAT-3 phosphorylation, arrests cell cycle at the G1 phase, inhibits cyclin D1 activity, reduces insulin levels, as well as IGF-1, TNFα, and IL-6 levels which reduce proliferation leading to apoptosis of neoplastic cells. In various tumours, including gynaecological cancers, metformin eliminates cancer stem cells (CSCs). Repositioning metformin as a possible antineoplastic option seems promising. The present authors suggest here that metformin could be a valuable tool for clinicians to help reduce cancer risk in elderly adults with diabetes.
Ovarian cancer
Endometrial cancer
Cancer stem cells
Back to top